On the way to in vitro platelet production.
Fiche publication
Date publication
août 2018
Journal
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GACHET Christian
Tous les auteurs :
Strassel C, Gachet C, Lanza F
Lien Pubmed
Résumé
The severely decreased platelet counts (10-30.10 platelets/μL) frequently observed in patients undergoing chemotherapy, radiation treatment or organ transplantation are associated with life-threatening increased bleeding risks. To circumvent these risks, platelet transfusion remains the treatment of choice, despite some limitations which include a limited shelf-life, storage-related deterioration, the development of alloantibodies in recipients and the transmission of infectious diseases. A sustained demand has evolved in recent years for controlled blood products, free of infectious, inflammatory and immune risks. As a consequence, the challenge for blood centers in the near future will be to ensure an adequate supply of blood platelets, which calls for a reassessment of our transfusion models. To meet this challenge, many laboratories are now turning their research efforts towards the in vitro and customized production of blood platelets.
Mots clés
Clinical alternative, In vitro cultured platelets, Plaquettes de culture, Platelet production, Production de plaquettes, Substitut transfusionnel, Transfusion
Référence
Transfus Clin Biol. 2018 Aug 24;: